Trial Profile
Phase II/III trial of Imprime PGG in patients with Haematological cancer
Status:
Planning
Phase of Trial:
Phase II/III
Latest Information Update: 01 Mar 2016
Price :
$35
*
At a glance
- Drugs Odetiglucan (Primary)
- Indications Haematological malignancies
- Focus Registrational; Therapeutic Use
- Sponsors Biothera
- 01 Mar 2016 New trial record